Minnesota Multidisciplinary Vasculitis Program

m2vp-group-img

Front Row L to R: S. Thaker, S. Reule, M. Rheault, H. Boyer, C. Fanola, D. Pearson, H. Muster
Back Row L to R: P. Nachman, S. Rajala, L. Ghazi, M. Beard, P. Fazeli, K. Woerner, D. Mueller, M. Pritzker, P. Ardnt

Mission

To provide patients with systemic inflammatory disease or vasculitis with cutting-edge, individualized, comprehensive and integrated multidisciplinary care and access to clinical trials.

Covered Diseases

  • Systemic vasculitis:
    • Small vessel vasculitis (ANCA-vasculitis, Anti-GBM disease, IgA Vasculitis)
    • Medium vessel vasculitis 
    • Large vessel vasculitis
  • Systemic Lupus Erythematosus

Goals

  • Provide patients with complex systemic diseases with multidisciplinary care which is organized, streamlined and efficient.
  • Provide community physicians and providers with a portal for efficient peer-to-peer consultation or referral.
  • Provide patients with access to cutting-edge clinical trials.
  • Facilitate translational research.
  • Provide a venue for health care providers training in the care of patients with complex systemic diseases.
     

Multidisciplinary Team

Cardiology

Dermatology

Nephrology

Otolaryngology (ENT)

Pulmonary

Rheumatology

Ongoing Clinical Trials

ANCA Vasculitis

Coming soon!

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Phase 2 Trial

Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus

Principal Investigator

Parastoo Fazeli, MD

Study Coordinator

Julie Scherber
sche0245@umn.edu 

CLINICAL TRIAL


Phase 3 Trial

A Two-year, Phase III Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 mg s.c. Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis 

Principal Investigator

Patrick H. Nachman, MD

Co-Investigators

Surabhi Thakar, MD

Parastoo Fazeli, MD

Study Coordinator

Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu

CLINICAL TRIAL


Phase 3 Trial

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)

Principal Investigator

Surabhi Thakar, MD

Study Coordinator

Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL